Prioritizing hits from phenotypic high-content screens

Current Opinion in Drug Discovery and Development

Volumn 11, Issue 3, 2008, Pages 338-345

  Low, J ^a   Stancato, L ^a   Lee, J ^a   Sutherland, J J ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Dendrogram; High content; Imaging; Phenotypic; Screening

Indexed keywords

RNA;

BIOCHEMISTRY; CLUSTER ANALYSIS; DATA ANALYSIS; DRUG DESIGN; DRUG SCREENING; HIGH CONTENT SCREENING; IN VITRO STUDY; MEDICAL TECHNOLOGY; MOLECULAR IMAGING; PHENOTYPE; REVIEW; RNA INTERFERENCE; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ANIMALS; BIOLOGICAL ASSAY; CLUSTER ANALYSIS; COMPUTATIONAL BIOLOGY; COMPUTER GRAPHICS; COMPUTER-AIDED DESIGN; DRUG DESIGN; HUMANS; MOLECULAR STRUCTURE; PHENOTYPE; PROTEIN CONFORMATION; REFERENCE STANDARDS; RNA INTERFERENCE; STRUCTURE-ACTIVITY RELATIONSHIP; TECHNOLOGY, PHARMACEUTICAL;

EID: 42449102225     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Sams-Dodd F: Target-based drug discovery: Is something wrong? Drug Disc Today (2005) 10(2):139-147.
2. Neumann B, Held M, Liebel U, Erfle H, Rogers P, Pepperkok R, Ellenberg J: High-throughput RNAi screening by time-lapse imaging of live human cells. Nat Methods (2006) 3(5):385-390.
3. Low J, Huang S, Dowless M, Blosser W, Vincent T, Davis S, Hodson J, Koller E, Marcusson E, Blanchard K, Stancato L: High-content imaging analysis of the knockdown effects of validated siRNAs and antisense oligonucleotides. J Biomol Screen (2007) 12(6):775-788.
4. Loo LH, Wu LF, Altschuler SJ: Image-based multivariate profiling of drug responses from single cells. Nat Methods (2007) 4(5):445-453. • Describes a sophisticated data analysis using support vector machine modeling for differentiating the anti-proliferative effects of 100 drugs and reference compounds. This method is used to identify distinct phenotypes associated with different compound concentrations and demonstrates how these effects can be presented visually.
5. Eggert US, Mitchison TJ: Small-molecule screening by imaging. Curr Opin Chem Biol (2006) 10(3):232-237.
6. Haney SA, LaPan P, Pan J, Zhang J: High-content screening moves to the front of the line. Drug Disc Today (2006) 11(19-20):889-894.
7. Lang P, Yeow K, Nichols A, Scheer A: Cellular imaging in drug discovery. Nat Rev Drug Discov (2006) 5(4):343-356.
8. Rausch O: High-content cellular screening. Curr Opin Chem Biol (2006) 10(4):316-320.
9. Korn K, Krausz E: Cell-based high-content screening of small-molecule libraries. Curr Opin Chem Biol (2007) 11(5):503-510.
10. Hart CP: Finding the target after screening the phenotype. Drug Disc Today (2005) 10(7):513-519.
11. Terstappen GC, Schlüpen C, Raggiaschi R, Gaviraghi G: Target deconvolution strategies in drug discovery. Nat Rev Drug Discov (2007) 6(11):891-903.
12. Lee S, Howell B, Kunapuli P: Cell imaging assays for G protein-coupled receptor internalization: Application to high-throughput screening. Methods Enzymol (2006) 414:79-98.
13. Berlage T: Analyzing and mining image databases. Drug Disc Today (2005) 10(11):795-802.
14. 2/M-arrested cells at low concentrations of the compound.
15. Barabasz A, Foley B, Otto JC, Scott A, Rice J: The use of high-content screening for the discovery and characterization of compounds that modulate mitotic index and cell cycle progression by differing mechanisms of action. Assay Drug Dev Technologies (2006) 4(2):153-163.
16. Perlman ZE, Slack MD, Feng Y, Mitchison TJ, Wu LF, Altschuler SJ: Multidimensional drug profiling by automated microscopy. Science (2004) 306(5699):1194-1198. •• Describes the profiling of 100 drugs and reference compounds for their concentration-dependent effects on DNA content and 10 fluorescent markers in the first application of its kind. The correlation of 10 blinded compounds to compounds of known mechanism demonstrated the ability of cellular profiles to predict the mechanism of uncharacterized compounds.
17. Vogt A, Tamewitz A, Skoko J, Sikorski RP, Giuliano KA, Lazo JS: The benzo[c]phenanthridine alkaloid, sanguinarine, is a selective, cell-active inhibitor of mitogen-activated protein kinase phosphatase-1. J Biol Chem (2005) 280(19):19078-19086.
18. Huang S, Yeo AA, Li SD: Modification of Kolmogorov-Smirnov test for DNA content data analysis through distribution alignment. Assay Drug Dev Technologies (2007) 5(5):663-671.
19. Dürr O, Duval F, Nichols A, Lang P, Brodte A, Heyse S, Besson D: Robust hit identification by quality assurance and multivariate data analysis of a high-content, cell-based assay. J Biomol Screen (2007) 12(8):1042-1049.
20. Young DW, Bender A, Hoyt J, McWhinnie E, Chirn GW, Tao CY, Tallarico JA, Labow M, Jenkins JL, Mitchison TJ, Feng Y: Integrating high-content screening and ligand-target prediction to identify mechanism of action. Nat Chem Biol (2008) 4(1):59-68. •• Describes the use of factor analysis to simplify the interpretation of highcontent parameters relevant to cell cycle regulation, and how compoundinduced effects can be understood in the context of predicted biochemical profiles and structure-activity relationships.
21. Tanaka M, Bateman R, Rauh D, Vaisberg E, Ramachandani S, Zhang C, Hansen KC, Burlingame AL, Trautman JK, Shokat KM, Adams CL: An unbiased cell morphology-based screen for new, biologically active small molecules. PLoS Biol (2005) 3(5):e128. •• Describes the assessment of the morphological effects of 107 compounds against 5 cell lines; PP2, a close analog of the Fyn inhibitor, gave a distinct phenotype in two out of five cell lines, which was attributed to CBR1 inhibition using biochemical in vitro assays, affinity purification of the analog-CBR1 complex and X-ray crystallography. The lack of an apparent relationship between its mechanism of action (in the absence of anthracyclines) and the observed phenotypic response supports the notion that screens measuring a broad range of cell features can differentiate compounds, even when the pharmacological attributes that distinguish them were not explicitly considered in devising the screen.
22. Conrad C, Erfle H, Warnat P, Daigle N, Lörch T, Ellenberg J, Pepperkok R, Eils R: Automatic identification of subcellular phenotypes on human cell arrays. Genome Res (2004) 14(6):1130-1136
23. Tao CY, Hoyt J, Feng Y: A support vector machine classifier for recognizing mitotic subphases using high-content screening data. J Biomol Screen (2007) 12(4):490-496.
24. Low J, Huang S, Blosser W, Dowless M, Stancato L: High-content imaging characterization of the eukaryotic cell cycle. Cancer Res (2008): manuscript submitted.
25. Perlman ZE, Mitchison TJ, Mayer TU: High-content screening and profiling of drug activity in an automated centrosomeduplication assay. ChemBioChem (2005) 6(1):145-151.
26. Yang J, Shamji A, Matchacheep S, Schreiber SL: Identification of a small-molecule inhibitor of class Ia PI3Ks with cell-based screening. Chem Biol (2007) 14(4):371-377.
27. Yarrow JC, Totsukawa G, Charras GT, Mitchison TJ: Screening for cell migration inhibitors via automated microscopy reveals a Rho-kinase inhibitor. Chem Biol (2005) 12(3):385-395.
28. Richards GR, Smith AJ, Parry F, Platts A, Chan GK, Leveridge M, Kerby JE, Simpson PB: A morphology- and kinetics-based cascade for human neural cell high-content screening. Assay Drug Dev Technologies (2006) 4(2):143-152. • Describes a screen for modulators of neural outgrowth in human neural precursor cultures that identified a number of hits that were characterized mechanistically by repeating the experiments in the presence of inhibitors of pathways involved in neurite outgrowth.
29. Bakal C, Aach J, Church G, Perrimon N: Quantitative morphological signatures define local signaling networks regulating cell morphology. Science (2007) 316(5832):1753-1756.
30. Moffat J, Sabatini DM: Building mammalian signaling pathways with RNAi screens. Nat Rev Mol Cell Biol (2006) 7(3):177-187.
31. Haney SA: RNAi and high-content screening in target identification and validation. IDrugs (2005) 8(12):997-1001.
32. Eggert US, Kiger AA, Richter C, Perlman ZE, Perrimon N, Mitchison TJ, Field CM: Parallel chemical genetic and genome-wide RNAi screens identify cytokinesis inhibitors and targets. PLoS Biol (2004) 2(12):e379.
33. Kittler R, Pelletier L, Heninger AK, Slabicki M, Theis M, Miroslaw L, Poser I, Lawo S, Grabner H, Kozak K, Wagner J et al: Genome-scale RNAi profiling of cell division in human tissue culture cells. Nat Cell Biol (2007) 9(12):1401-1412.
34. Fliri AF, Loging WT, Thadeio PF, Volkmann RA: Biological spectra analysis: Linking biological activity profiles to molecular structure. Proc Natl Acad Sci USA (2005) 102(2):261-266.
35. Fliri AF, Loging WT, Thadeio PF, Volkmann RA: Analysis of drug-induced effect patterns to link structure and side effects of medicines. Nat Chem Biol (2005) 1(7):389-397.
36. Vogt A, Cooley KA, Brisson M, Tarpley MG, Wipf P, Lazo JS: Cell-active dual specificity phosphatase inhibitors identified by high-content screening. Chem Biol (2003) 10(8):733-742.
37. Lundholt BK, Linde V, Loechel F, Pedersen HC, Møller S, Praestegaard M, Mikkelsen I, Scudder K, Bjørn SP, Heide M, Arkhammar PO et al: Identification of Akt pathway inhibitors using redistribution screening on the FLIPR and the IN Cell 3000 analyzer. J Biomol Screen (2005) 10(1):20-29. • Describes the identification of two classes of Akt translocation inhibitors using a high-content screen. The inhibitors were further characterized with other high-content assays measuring multiple pathway endpoints, and biochemical in vitro assays.
38. Hardcastle A, Tomlin P, Norris C, Richards J, Cordwell M, Boxall K, Rowlands M, Jones K, Collins I, McDonald E, Workman P et al: A duplexed phenotypic screen for the simultaneous detection of inhibitors of the molecular chaperone heat shock protein 90 and modulators of cellular acetylation. Mol Cancer Ther (2007) 6(3):1112-1122.
39. MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW et al: Identifying off-target effects and hidden phenotypes of drugs in human cells. Nat Chem Biol (2006) 2(6):329-337. • Describes the application of a high-content assay panel that recapitulated the pharmacology of known drugs and suggested a number of 'hidden' phenotypes, identifying potentially useful new applications for existing drugs.
40. Fuchs F, Boutros M: Cellular phenotyping by RNAi. Brief Funct Genomic Proteomic (2006) 5(1):52-56.
41. Williams RG, Kandasamy R, Nickischer D, Trask OJ Jr, Laethem C, Johnston PA, Johnston PA: Generation and characterization of a stable MK2-EGFP cell line and subsequent development of a high-content imaging assay on the Cellomics ArrayScan platform to screen for p38 mitogen-activated protein kinase inhibitors. Methods Enzymol (2006) 414:364-389.
42. Nickischer D, Laethem C, Trask OJ Jr, Williams RG, Kandasamy R, Johnston PA, Johnston PA: Development and implementation of three mitogen-activated protein kinase (MAPK) signaling pathway imaging assays to provide MAPK module selectivity profiling for kinase inhibitors: MK2-EGFP translocation, c-Jun, and ERK activation. Methods Enzymol (2006) 414:389-418.
43. Kau TR, Schroeder F, Ramaswamy S, Wojciechowski CL, Zhao JJ, Roberts TM, Clardy J, Sellers WR, Silver PA: A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells. Cancer Cell (2003) 4(6):463-476.
44. Klekota J, Brauner E, Schreiber SL: Identifying biologically active compound classes using phenotypic screening data and sampling statistics. J Chem Inf Model (2005) 45(6):1824-1836. • The application of techniques that are commonly used for analyzing gene expression data demonstrates the utility of considering structural classes of hits, rather than examination of individual hits.
45. Ross-Macdonald P: Drug discovery without a molecular target: The road less traveled. Expert Rev Mol Diagnostics (2007) 7(1):1-4.